The efficacy of macrolides for urogenital infections

A.V. Kuz’menko, V.V. Kuz’menko, T.A. Gyaurgiev

Burdenko Voronezh State Medical University

Currently, non-gonococcal microbes become the leading causative agents of sexually transmitted infections. It was demonstrated that these microbes provoke non-specific urethritis and pelvic inflammatory disorders.

and safety of roxithromycin for non-gonococcal urethritis in men were published Many authors report on the significant increase in the occurrence of inflammatory pelvic disorders associated with Mycoplasma hominis and Ureaplasma spp. in recent years. In men, the most common causative agents of non-gonococcal urethritis are Chlamydia trachomatis (23–55%), Ureaplasma urealyticum (20–40%), Mycoplasma genitalium (12–25%), Trichomonas vaginalis (2–5%). Moreover, mixed infections are commonly diagnosed in patients with non-specific urethritis.

Considering the growing role of intracellular bacterial pathogens in pelvic inflammatory disorders in women and non-gonococcal urethritis in men, macrolides gain significance in the treatment for these infections. Among macrolides, the most popular agent is roxithromycin. In recent years, a number of studies on the clinical efficacy. These studies have demonstrated that this drug is an effective and safe therapy for non-gonococcal urethritis and pelvic inflammatory disorders.

Keywords: sexually transmitted infections, urogenital infections, sexually transmitted infections, vaginitis, sexually transmitted infections, macrolides, roxithromycin.

For citation: Kuz’menko A.V., Kuz’menko V.V., Gyaurgiev T.A. The efficacy of macrolides for urogenital infections. RMJ. 2019;10:46–49.